Roche Acquires Tusk Therapeutics for its Regulatory T Cell Research in Oncology
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 10 (Table of Contents)
Published: 5 Oct-2018
DOI: 10.3833/pdr.v2018.i10.2362 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Expanding its oncology pipeline, Roche has acquired T-regulatory (Treg) cell specialist, Tusk Therapeutics, in a deal worth potentially up to €655 M (US$766 M)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS